Lumacaftor/ Ivacaftor improves exercise tolerance in patients with Cystic Fibrosis and severe airflow obstruction.
Peter A B WarkKim CooksonTheeba ThiruchelvamJohn BrannanDouglas J DorahyPublished in: BMC pulmonary medicine (2019)
This was an observational trial conducted on individuals who became eligible to receive LUM/IVA. All investigations were carried out as part of routine clinical care. The trial was registered in retrospect on the 13/5/2019 on the Australian New Zealand Clinical Trials registry; ACTRN12619000708156 .
Keyphrases
- clinical trial
- cystic fibrosis
- phase iii
- phase ii
- end stage renal disease
- study protocol
- ejection fraction
- healthcare
- newly diagnosed
- palliative care
- chronic kidney disease
- peritoneal dialysis
- randomized controlled trial
- clinical practice
- open label
- early onset
- pain management
- body composition
- chronic pain
- placebo controlled